6505--Glipizide Tablets

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

NAC PHARMACEUTICALS (36E797)

Contract Value

Not provided

Codes & Classification
Solicitation Number

36E79726R0031

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

None

Place of Performance

-

SourceSAM
Documents1
The Department of Veterans Affairs (VA) National Acquisition Center (NAC) has announced a forthcoming procurement opportunity for Glipizide Tablets, as detailed in presolicitation notice 36E79726R0031. This initiative is designed to secure a reliable, uninterrupted supply of Glipizide Tablets for a broad spectrum of federal healthcare entities, including the VA (encompassing Consolidated Mail Order Pharmacies and State Veterans Homes under Option 2), the Department of Defense (DoD), the Bureau of Prisons (BOP), the Indian Health Service (IHS), and the Federal Health Care Center (FHCC). The primary objective of this procurement is to establish a single-source contract with a responsible offeror capable of meeting the comprehensive supply requirements for Glipizide Tablets over a base period of one year, with the possibility of four additional one-year option periods. The contract will support the distribution of these pharmaceutical products through the VA’s and DoD’s respective Pharmaceutical Prime Vendor Programs, ensuring consistent and efficient delivery to end users. Key requirements for this solicitation include the provision of Glipizide Tablets in various strengths and packaging configurations. Specifically, the VA anticipates annual needs for both 5mg and 10mg tablets, with packaging sizes ranging from 90, 180, and 360 count bottles (unit of use), as well as bulk packaging in 500 or 1,000 count bottles (non-unit of use). The estimated annual usage for each configuration is substantial, with the highest demand for 5mg tablets in 90 and 180 count bottles, and 10mg tablets in 180 count bottles. Offerors must supply products under the exact name that appears on the product label, accompanied by a unique National Drug Code (NDC) specific to the offeror. The successful contractor’s label and NDC will be the only identifiers on the product, and relabeling over another manufacturer’s label is strictly prohibited. However, VA labels must be able to securely adhere over the contractor’s label for internal tracking and compliance purposes. Packaging specifications are detailed and must be strictly adhered to. Bottles must be of a minimum 120cc volume, with a cylindrical body and a minimum circumference of 5.75 inches. The safety cap must not exceed the bottle’s diameter and should be convertible to a non-safety cap if required. The label area must accommodate a 5.25 x 2 inch label, with an additional 0.5 inch to ensure barcode visibility and clear display of expiration date and lot number. This procurement is classified under NAICS code 325412 (Pharmaceutical Preparation Manufacturing), and the Product Service Code is 6505. The opportunity is unrestricted, allowing all responsible sources to submit proposals. The solicitation will be issued electronically in accordance with FAR Part 12 (Commercial Items) on or about July 27, 2026, with a tentative closing date of August 10, 2026. All documents and future amendments will be available exclusively through SAM.gov; no paper copies will be provided. Interested contractors are encouraged to monitor the SAM.gov listing for updates and amendments. All inquiries regarding this opportunity should be directed to the primary point of contact, Deb Fassl, at [email protected] or by phone at 708-786-5894. This procurement represents a significant opportunity for pharmaceutical manufacturers and suppliers with the capacity to meet stringent federal requirements for quality, labeling, packaging, and supply continuity. Contractors should carefully review the detailed specifications and ensure their ability to comply with all outlined requirements before preparing a response.